Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Neurology Rheumatology Diabetes / Metabolic Mental Health / Psychiatry Women's Health Dermatology Men's Health Rare Diseases
Clinical Trial ● Currently Recruiting NCT06447064

Cancer Loyalty Card Study 2 (CLOCS-2)

Cancer Loyalty Card Study 2 (CLOCS-2) — Recruiting • Oncology • NCT06447064.

📅 25 Mar 2026 ⏱ 4 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
NCT ID
NCT06447064
Sponsor
Imperial College London
Start
2026-02-04
ClinicaliQ Trial Snapshot
  • Cancer Loyalty Card Study 2 (CLOCS-2) — Recruiting • Oncology • NCT06447064.
  • Cancer is one of the leading causes of mortality worldwide and is responsible for an estimated 9.6 million deaths yearly. Cancer-related deaths can be reduced if patients are diagnosed and treated early. Delay in cancer diagnosis can occur at any point along….
  • Sponsor: Imperial College London.

Verify eligibility, endpoints and current status on the original source registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

Cancer is one of the leading causes of mortality worldwide and is responsible for an estimated 9.6 million deaths yearly. Cancer-related deaths can be reduced if patients are diagnosed and treated early. Delay in cancer diagnosis can occur at any point along the diagnostic spectrum, from the first observation of symptoms to the start of treatment. Diagnosing cancer when it is still at an early stage, before it has spread, gives surgery, radiotherapy and other treatments the best chance of working. Therefore, early diagnosis is the most important way to…

Eligibility Snapshot
  • (ALL): * Individuals aged >18 years of age * Individuals must be residing in the United Kingdom at the time of giving informed consent * Individuals must be registered with an NHS GP Practice * Individuals must meet the criteria of ONE of the groups. For example, to be eligible for Group 1 (Cases), individuals must have been diagnosed with one of the following cancer types in the last 24 months: Bladder, colorectal (bowel), endometrial, liver, oesophageal, ovarian, pancreatic, stomach (gastric), uterine, or vulval; whereas for Group 2 (Controls), individuals must not have received a cancer diagnosis of any type in the last 6 years (except where the diagnosis was of non-melanoma skin cancer). * Individuals must be a primary registered cardholder* of one of the loyalty cards listed below, and consent to share their loyalty card data with the study team * Tesco Clubcard * Boots Advantage Card * Provision of written informed consent * Willing and able to comply with all required study activities * The primary registered card holder, i.e., the person who is named on the loyalty card account, must also enrol into the study, if someone other than the registered primary card holder… Data sourced from ClinicalTrials.gov. Trial details may change — always check the primary source before clinical decisions.

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Head and Neck Cancers: Diagnosis and Management (NICE NG36)
Oncology · 27 Mar 2026
Refer urgently (two-week wait) any adult with unexplained persistent hoarseness, dysphagia, otalgia, oral ulceration lasting more than 3 weeks, or suspicious neck…
View guideline →
Clinical Brief
Women attending first NHS mammogram hits 10-year high as thousands more cancers found
Oncology · NHS England · 19 Feb 2026
Hundreds of thousands more women attended NHS breast screening last year and thousands more cancers were diagnosed early in England. New figures…
View brief →
Guideline
Ovarian Cancer: Recognition and Initial Management (NICE NG241)
Oncology · 27 Mar 2026
Perform CA125 blood test and pelvic ultrasound (including ovarian assessment) as first-line investigations in primary care when ovarian cancer is suspected based…
View guideline →
Guideline
Bladder Cancer: Diagnosis and Management (NICE NG2)
Oncology · 27 Mar 2026
Blue light cystoscopy with hexaminolevinate improves detection of recurrent bladder tumours compared to white light cystoscopy alone, particularly for carcinoma in situ.…
View guideline →
Guideline
Colorectal Cancer: Diagnosis and Management (NICE NG151)
Oncology · 27 Mar 2026
Refer adults with rectal bleeding plus abdominal pain, change in bowel habit, weight loss, iron-deficiency anaemia, or age >60 with unexplained symptoms…
View guideline →
Guideline
Non-Hodgkin’s Lymphoma: Diagnosis and Management (NICE NG52)
Oncology · 27 Mar 2026
Refer urgently via suspected cancer pathway any patient with persistent lymphadenopathy (lymph nodes >1 cm short axis) or splenomegaly without clear infective…
View guideline →